Skip to main content

Immunotherapies for CNS tumors

Review the latest trials of immune checkpoint inhibitors, vaccine therapy, oncolytic viruses, and CAR T-cell therapy, and the neurological toxicities and physiological barriers that make treating CNS tumors uniquely challenging.

Read more

Editor's Choice

Drug-induced pulmonary toxicity

Drug-induced interstitial lung disease has emerged as a clinically significant complication in the era of immunotherapy and biologics. Learn how to diagnose and manage this potentially severe adverse event.

Common food additives tied to increased cancer and diabetes risks

Data from a large cohort has revealed a significant association between higher consumption of certain food preservatives and an increased incidence of cancer and type 2 diabetes.

Revisiting the use of steroids in oncology

Glucocorticoids are cornerstone agents in oncology due to their potent anti-inflammatory, immunosuppressive, and antitumor properties. But it is is crucial to strike a balance between therapeutic benefit and harm.

Long-term response to nivolumab in gastric cancer

Adjuvant treatment for metastatic melanoma with six cycles of nivolumab also led to a sustained response of the concurrent early-stage gastric cancer in this patient, who achieved long-term disease-free survival with minimal treatment.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Aplastic anemia: managing special patient subgroups and challenging cases (Link opens in a new window)

Learn more about the importance of adapting treatment approaches for special patient populations (eg, elderly or pregnant patients) in this third module of our interactive e-Learning program on diagnosing and treating aplastic anemia.

Supported by:
  • Pfizer
Developed by: Springer Health+ IME
Learn more

Are you up to date on targeted therapies for relapsed/refractory AML? 

Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.

Supported by: independent educational grant from Rigel

Find out more
SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

Join Professor Joy Ho as she leads a panel of Asia-Pacific-based experts, discussing real-life patient cases and their experiences with CAR T-cell therapy for the treatment of R/R DLBCL or R/R FL. Learn about how to identify appropriate patients for CAR T-cell therapy and how to optimize outcomes with this treatment modality. Gain insights into essential aspects of pre- and post-infusion management, as well as important considerations for treatment sequencing.

This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.

Sponsored by:
  • Novartis Pharma AG
Prof. Joy Ho
Prof. William Hwang
Dr. Kentaro Fukushima
Prof. Dok Hyun Yoon
Prof. Miki Ando
Developed by: Springer Health+
Learn more
Video

Case Studies

Long-term response to nivolumab in gastric cancer

Adjuvant treatment for metastatic melanoma with six cycles of nivolumab also led to a sustained response of the concurrent early-stage gastric cancer in this patient, who achieved long-term disease-free survival with minimal treatment.

Primary leiomyosarcoma of the colon

Colonic leiomyosarcoma is a rare and aggressive tumor that is often difficult to diagnose preoperatively, especially in a case such as this where multiple biopsies were inconclusive.

Hodgkin lymphoma in a patient with Behçet disease

A case illustrating a rare but important association between Behçet disease and Hodgkin lymphoma, possibly mediated by immune dysregulation and chronic immunosuppression.

Keynote webinar | Spotlight on progress in colorectal cancer

On-demand video coming soon

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Notify me

Current Reviews

Medication-associated thyroid eye disease: a review

Thyroid eye disease (TED) is the most common cause of orbital disease. TED most commonly arises due to Graves’ disease, however, may occur in hypothyroidism and euthyroid states. These thyroid disorders are typically de novo autoimmune processes …

Gene fusion–driven cutaneous mesenchymal neoplasms: An updated review emphasizing the emerging entities

The advent of next-generation sequencing (NGS) has significantly advanced the classification of mesenchymal neoplasms, allowing for the identification of novel gene fusion–driven entities, also in the cutaneous setting. These molecular discoveries …

Efficacy of sacituzumab govitecan, a Trop-2-directed antibody–drug conjugate, in metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease with limited treatment options. Antibody–drug conjugates (ADCs), particularly those targeting trophoblast cell-surface antigen 2 (Trop‑2), have emerged as an effective …

Episode 22: Celebrating 25 years of TKIs in CML

Marking a major milestone in chronic myeloid leukemia treatment

Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before.

In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely.

Dr. Jorge Cortes
Listen now
Podcast

CME & eLearning

SPONSORED

Masterclass webinar: Expert review of CAR T-cell therapy patient cases in R/R DLBCL or R/R FL

Professor Joy Ho and a panel of Asia-Pacific-based experts will examine real-life patient cases in this Masterclass, exchanging insights into their clinical experiences of using CAR T-cell therapy to treat patients with R/R DLBCL or R/R FL.

This educational activity is not intended for healthcare professionals based in the UK, US, or off-label Asia-Pacific countries.

Sponsored by:
  • Novartis Pharma AG
SPONSORED

CAR T-cell therapy medical education hub

This hub presents a curated selection of educational materials focused on the latest clinically relevant topics related to the use of chimeric antigen receptor (CAR) T‑cell therapy for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and R/R follicular lymphoma (FL).

This content has been developed in collaboration with and funded by the sponsor Novartis Pharma AG and is not intended for healthcare professionals based in the UK and US.

Sponsored by:
  • Novartis Pharma AG

The AML expert series

Hear directly from experts in acute myeloid leukemia about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME

Further Reading

Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis

Breast imaging is essential for detecting breast cancer, but it also identifies a range of findings beyond malignant lesions, including benign and indeterminate lesions. The latter, also known as “B3 lesions” according to European and UK …

Medication-associated thyroid eye disease: a review

Thyroid eye disease (TED) is the most common cause of orbital disease. TED most commonly arises due to Graves’ disease, however, may occur in hypothyroidism and euthyroid states. These thyroid disorders are typically de novo autoimmune processes …

Risk-adapted management in stage I testicular germ-cell tumors: long-term outcomes from a single-center cohort (1994–2023)

Testicular germ-cell tumors (TGCT) are the most common solid malignancy in young men and a paradigm of curable cancer. Around two-thirds to three-quarters present with clinical stage I disease, where long-term cancer-specific survival (CSS) …

Related topics

Immunotherapies for CNS tumors

Review the latest trials of immune checkpoint inhibitors, vaccine therapy, oncolytic viruses, and CAR T-cell therapy, and the neurological toxicities and physiological barriers that make treating CNS tumors uniquely challenging.

Read more
Image Credits
Tumor cell surrounded with immune cells/© Nevio / Generated with AI / Stock.adobe.com, CT scan of pembrolizumab-treated patient/© 2026, Josmar J. Ríos Poveda et al, Pulm Ther, Man standing in a supermarket aisle and reading the label on a grocery item/© Giselleflissak / Getty Images / iStock (symbolic image with model), Colorful pills spilling from a bottle/© igoriss / Getty Images / iStock, Syringe and vial of medicine/© Алексей Громов / Stock.adobe.com, Aplastic Anemia/© Springer Healthcare IME, Older man sitting on the edge of a bed/© andreswd / E+ / Getty Images (symbolic image with model), Mammogram image on a screen/© Valerii Apetroaiei / stock.adobe.com, Close-up of subcutaneous injection syringe/© Laures / Getty Images / iStock, CAR T-cell attacking cancer cells/© LoveLive/stock.adobe.com, Colonoscopy of patient with primary leiomyosarcoma of the colon/© 2025, Dae Hee Pyo et al, World J Surg Onc, FDG PET-CT of patient with Behçet disease and Hodgkin lymphoma/© 2025, Matthew Coulter et al, under exclusive licence to International League of Associations for Rheumatology (ILAR), Clin Rheumatol, Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images, Medicine Matters Podcast promo image/© Springer Medizin GmbH, T-cell expressing chimeric antigen receptor (CAR) in the cell membrane; DNA is exposed from the T-cell to highlight the genetic engineering involved in creating CAR T-cells/© LoveLive/stock.adobe.com, Leukemia background in bright colors, including white and red blood cells in realistic style/© Double Brain/Shutterstock.com, Fundus scan in vitreoretinal lymphoma/© 2025, Atsunobu Takeda et al, Jpn J Ophthalmol, Antibody drug conjugates/© huenstructurebio.com / stock.adobe.com, Chest x-ray showing patchy infiltrates with internal lucency suggestive of cavitation/© 2025, Akela Ghazawi et al, BMC Infect Dis, Red heart on an electrocardiogram trace/© manassanant / Stock.adobe.com, Conceptual illustration of gut microbiome/© ArtemisDiana / Getty Images / iStock